NCT02346955

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 \[MK-6018\]), administered intravenously as monotherapy and in combination with Pembrolizumab (MK-3475), in participants with selected advanced or recurrent malignancies. Escalating multiple doses will be evaluated to determine the recommended dose for Phase 2 clinical studies.

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Feb 2015

Typical duration for phase_1

Geographic Reach
2 countries

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 9, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 27, 2015

Completed
5 days until next milestone

Study Start

First participant enrolled

February 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
Last Updated

August 27, 2020

Status Verified

August 1, 2020

Enrollment Period

2 years

First QC Date

December 9, 2014

Last Update Submit

August 25, 2020

Conditions

Keywords

CancerOncologycCAM Biotherapeutics LtdImmunomodulatory therapyCM-24Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1)NSCLC (adenocarcinoma)UvealAcralMucosalCutaneousColorectalGastricOvarianBladderMK-6018-001

Outcome Measures

Primary Outcomes (3)

  • Number of participants with Adverse Events (AEs)

    From time of first dose until the end of follow-up (up to 123 weeks)

  • Number of participants discontinuing study drug due to AEs

    From time of first dose until the end of follow-up (up to 105 weeks)

  • Number of participants with a Dose Limiting Toxicity (DLT)

    From time of first dose until the end of follow-up (up to 12 weeks)

Secondary Outcomes (7)

  • Maximum drug concentration in serum/plasma (Cmax)

    For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.

  • Time to reach Cmax in serum/plasma (Tmax)

    For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.

  • Terminal-phase elimination half-life in serum/plasma (t1/2)

    For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.

  • Area under the plasma/serum concentration versus time curve from time zero to the last measured time (AUC 0-T)

    For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.

  • Area under the plasma/serum concentration versus time curve from time zero to infinity (AUC 0-∞)

    For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.

  • +2 more secondary outcomes

Study Arms (9)

Cohort A Monotherapy Dose Escalation

EXPERIMENTAL

Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.

Biological: CM-24 (MK-6018)

Cohort B Combination Dose Escalation

EXPERIMENTAL

Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.

Biological: CM-24 (MK-6018)Biological: Pembrolizumab (MK-3475)

Cohort C Monotherapy Expansion

EXPERIMENTAL

Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.

Biological: CM-24 (MK-6018)

Cohort D Monotherapy Expansion

EXPERIMENTAL

Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.

Biological: CM-24 (MK-6018)

Cohort E Monotherapy Expansion

EXPERIMENTAL

Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.

Biological: CM-24 (MK-6018)

Cohort C1 Combination Expansion

EXPERIMENTAL

Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).

Biological: CM-24 (MK-6018)Biological: Pembrolizumab (MK-3475)

Cohort D1 Combination Expansion

EXPERIMENTAL

Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).

Biological: CM-24 (MK-6018)Biological: Pembrolizumab (MK-3475)

Cohort E1 Combination Expansion

EXPERIMENTAL

Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).

Biological: CM-24 (MK-6018)Biological: Pembrolizumab (MK-3475)

Cohort F Combination Expansion

EXPERIMENTAL

Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).

Biological: CM-24 (MK-6018)Biological: Pembrolizumab (MK-3475)

Interventions

CM-24 (MK-6018)BIOLOGICAL

humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion

Also known as: Anti-CEACAM1
Cohort A Monotherapy Dose EscalationCohort B Combination Dose EscalationCohort C Monotherapy ExpansionCohort C1 Combination ExpansionCohort D Monotherapy ExpansionCohort D1 Combination ExpansionCohort E Monotherapy ExpansionCohort E1 Combination ExpansionCohort F Combination Expansion

200 mg of Pembrolizumab by IV infusion

Also known as: KEYTRUDA®
Cohort B Combination Dose EscalationCohort C1 Combination ExpansionCohort D1 Combination ExpansionCohort E1 Combination ExpansionCohort F Combination Expansion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females ≥18 years of age
  • Participants in the Dose Escalation portion must have one of the following advanced or recurrent malignancies: gastrointestinal (colorectal or gastric); ovarian; melanoma; non-small cell lung adenocarcinoma; or bladder.
  • Participants in the Monotherapy Expansion Cohort must have one of the following advanced or recurrent malignancies: cutaneous melanoma showing primary progression following treatment with an anti-programmed cell death (PD) or anti-PDL1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.
  • Participants in the Combination Expansion Cohorts must have one of the following advanced or recurrent malignancies: non-small cell lung adenocarcinoma or cutaneous melanoma showing primary progression following treatment with an anti-PD1 or anti-PD-L1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.
  • Melanoma with BRAF V600E or V600K mutation-positive melanoma must have progressed on, or were intolerant to, prior BRAF- or MEK-inhibitor therapy
  • Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapy
  • Must have adequate hematologic, renal, and liver function
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Females must not be pregnant (negative human chorionic gonadotropin test within 72 hours prior to receiving the first dose of study medication) or breastfeeding
  • Women of childbearing potential and male participants must agree to use adequate contraception throughout the study and for up to 180 days after study treatment
  • An estimated life expectancy of at least 3 months
  • Must consent to provide an archival tumor biopsy sample at any time point from screening to study exit
  • Must consent to allow the acquisition of new tissue biopsy samples during the study

You may not qualify if:

  • History of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodies
  • History of other active malignancy within the prior 2 years
  • History of insulin-dependent or uncontrolled Diabetes Mellitus
  • History of inflammatory bowel disease
  • Autoimmune disorders
  • Known HIV and/or Hepatitis B or C infections
  • Known systemic bleeding or platelet disorder
  • Receipt of live vaccines with 4 weeks (28 days) of study
  • History or evidence of non-infectious pneumonitis that required steroids or current pneumonitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Call for Information (Investigational Site 0003)

Los Angeles, California, 90095, United States

Location

Call for Information (Investigational Site 0004)

New Haven, Connecticut, 06513, United States

Location

Merck Sharp & Dohme Co. Ltd.

Hod HaSharon, Israel

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungMelanomaUrinary Bladder NeoplasmsColorectal NeoplasmsStomach NeoplasmsOvarian NeoplasmsNeoplasmsAdenocarcinoma

Interventions

pembrolizumab

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsSkin DiseasesSkin and Connective Tissue DiseasesUrologic NeoplasmsUrogenital NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesStomach DiseasesEndocrine Gland NeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleGenital Neoplasms, FemaleGenital DiseasesEndocrine System DiseasesGonadal DisordersCarcinomaNeoplasms, Glandular and Epithelial

Study Officials

  • Medical Director

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 9, 2014

First Posted

January 27, 2015

Study Start

February 1, 2015

Primary Completion

February 1, 2017

Study Completion

February 1, 2017

Last Updated

August 27, 2020

Record last verified: 2020-08

Locations